List of Excipients in Branded Drug VASCEPA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	GELATIN
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	GLYCERIN
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	MALTITOL
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	SORBITOL
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	TOCOPHEROL
Amarin Pharma Inc	VASCEPA	icosapent ethyl	52937-001	WATER

Last updated: August 2, 2026

Executive summary: VASCEPA is an oral icosapent ethyl product whose commercial differentiation comes from purified EPA, cardiovascular-risk reduction data, and prescription positioning rather than a complex excipient system. The marketed capsules use a conventional gelatin-based shell with glycerin, sorbitol, purified water, and alpha-tocopherol-related oxidation control. The strongest excipient opportunities are oxidation management, capsule-shell substitution, release and stability optimization, and lower-cost generic manufacturing. Excipient changes can support generic competition, but they do not eliminate the need to address VASCEPA’s Orange Book patents, labeling restrictions, bioequivalence requirements, and food-effect considerations.

VASCEPA Excipient Strategy, Patent Landscape, and Commercial Opportunities

What is VASCEPA and which dosage forms use excipients?

VASCEPA is the brand name for icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, or EPA. Amarin markets VASCEPA as oral soft-gel capsules in 0.5-gram and 1-gram strengths. The approved uses are:

• As an adjunct to diet for adults with severe hypertriglyceridemia, generally triglycerides of at least 500 mg/dL.
• In combination with a maximally tolerated statin for adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional cardiovascular risk factors. [1]

The principal formulation challenge is the active ingredient itself. Icosapent ethyl is a lipophilic oil with limited aqueous solubility. The product is administered with food, and the label states that VASCEPA should be taken with meals. [1]

Product attribute	VASCEPA profile
Active ingredient	Icosapent ethyl
Active pharmaceutical ingredient class	Purified EPA ethyl ester
Dosage form	Oral soft-gel capsule
Strengths	0.5 g and 1 g
Primary excipient system	Gelatin, glycerin, sorbitol, purified water
Administration	With food
Key formulation risks	Oxidation, shell integrity, leakage, fill uniformity, food-effect performance
FDA pathway for generic	Abbreviated New Drug Application, or ANDA
Biosimilar pathway	Not applicable; VASCEPA is a small-molecule drug

The FDA label identifies the capsule shell as containing gelatin, glycerin, sorbitol, and purified water. The formulation also includes an antioxidant component intended to support product stability. [1]

What excipients are used in VASCEPA capsules?

The core excipient system is conventional for an oil-filled soft-gel product.

Capsule shell

Gelatin provides the structural shell. Glycerin and sorbitol act as plasticizers and influence flexibility, moisture retention, brittleness, and long-term shell stability. Purified water is part of the shell composition.

This combination is commercially established, but it creates manufacturing and market constraints:

• Gelatin is animal-derived and can create religious, dietary, and market-access limitations.
• Plasticizer ratios affect capsule hardness, brittleness, tackiness, and leakage.
• Shell water activity can influence oxidation and physical stability of the fill.
• Gelatin cross-linking can affect shell dissolution and release testing over time.

A non-gelatin shell could support vegetarian, vegan, halal, kosher, or region-specific positioning. Potential alternatives include modified starch, pullulan, hydroxypropyl starch, and hypromellose-based systems. These materials are not automatically substitutable. A new shell may change oxygen permeability, moisture transfer, dissolution, mechanical performance, and bioequivalence.

Oxidation-control excipients

Polyunsaturated fatty-acid derivatives are vulnerable to oxidation. The commercial opportunity is less about adding a large excipient load and more about controlling the entire oxygen-exposure profile:

• Antioxidant selection and concentration
• Oxygen content in the fill and headspace
• Nitrogen blanketing during manufacture
• Low-permeability packaging
• Light protection
• Chelator use where justified
• Control of peroxide and anisidine values
• Limits on trace metals and residual catalysts

Alpha-tocopherol is widely used in lipid formulations, but alternative antioxidant systems could improve stability, reduce odor, or simplify regional registration. Any change must be assessed against degradation products, capsule compatibility, impurity specifications, and toxicological acceptability.

Plasticizers and shell modifiers

Glycerin and sorbitol provide a platform for modifying capsule performance. A generic or line-extension developer could optimize:

• Shell elasticity
• Drying time
• Long-term brittleness
• Seal strength
• Dissolution after storage
• Resistance to temperature cycling
• Compatibility with high-throughput filling equipment

The commercial value is highest when the change reduces manufacturing rejects or improves shelf life without creating a new clinical or regulatory burden.

What excipient strategy is most commercially attractive for VASCEPA?

The best near-term strategy is an oxidation-controlled, bioequivalent soft-gel platform that reduces cost and improves manufacturing robustness.

Strategy	Commercial benefit	Main technical barrier	Regulatory burden
Lower-cost conventional gelatin shell	Reduces cost of goods	Shell leakage and stability	Moderate
Vegetarian or vegan shell	Expands patient and geographic access	Oxygen and moisture permeability	Moderate to high
Improved antioxidant system	Extends shelf life and reduces degradation	Compatibility and impurity control	Moderate
Nitrogen-controlled fill process	Reduces oxidation without changing excipients	Equipment and process validation	Moderate
Modified-release capsule	Potential dosing differentiation	Food effect and clinical performance	High
Smaller capsule or concentrated fill	Improves swallowability	Fill viscosity and dose uniformity	Moderate to high
Tamper-evident or adherence-oriented packaging	Supports specialty and chronic-care channels	Packaging validation	Low to moderate
Liquid or sachet presentation	May assist swallowing and administration	Dose uniformity and palatability	High

A conventional soft-gel generic is likely to have the clearest path. A differentiated shell or modified-release product can command higher pricing, but it increases development, stability, and regulatory risk.

What patents protect VASCEPA and how do they affect excipient opportunities?

VASCEPA’s patent position has included composition and method-of-use patents. Publicly litigated patents include U.S. Patent No. 8,278,353, directed to pharmaceutical compositions containing highly purified icosapent ethyl, and U.S. Patent No. 9,700,159, directed to cardiovascular-risk reduction methods involving icosapent ethyl. [2][3]

The patent estate matters differently for a generic excipient developer and an innovative reformulator:

• A conventional ANDA product must address applicable Orange Book-listed patents through certification or a statement.
• A formulation change does not automatically avoid a composition patent.
• A new capsule shell may avoid a narrow formulation claim only if the claims do not cover the active composition broadly.
• A product labeled only for severe hypertriglyceridemia may use a section viii statement to omit a patented cardiovascular-risk indication, subject to the scope of the listed claims and FDA labeling requirements.
• A new indication or delivery technology may require a 505(b)(2) application rather than an ANDA.

The U.S. Court of Appeals for the Federal Circuit affirmed a decision invalidating key Amarin patents asserted against Hikma, finding the challenged claims obvious. The decision materially reduced the ability to block skinny-label generic entry based on those patents. [3]

How many patents cover VASCEPA?

The answer depends on the date, jurisdiction, product strength, and whether the analysis includes expired, unlisted, pending, or non-U.S. patents. The FDA Orange Book is the controlling public source for patents listed against an approved product in the United States. [2]

For commercial diligence, the relevant categories are:

1. Active-ingredient and composition patents
2. Purity and manufacturing patents
3. Cardiovascular-risk reduction method patents
4. Hypertriglyceridemia method patents
5. Formulation and capsule patents
6. Pending applications and continuation patents
7. Regional patents outside the United States

The existence of a listed patent does not establish validity. The Hikma litigation illustrates that listed method-of-use patents can be vulnerable to obviousness challenges even when they create a formal Paragraph IV barrier.

When does VASCEPA lose exclusivity?

VASCEPA lost practical market exclusivity in the United States when generic icosapent ethyl products entered after litigation and settlement activity involving Amarin and generic applicants. Hikma launched a generic icosapent ethyl product in 2020 for the severe-hypertriglyceridemia indication using a restricted label. [3][4]

The exclusivity analysis has four separate components:

Exclusivity type	VASCEPA relevance
New chemical entity exclusivity	Expired before current generic entry
Orphan exclusivity	Not the principal U.S. protection for VASCEPA
Pediatric exclusivity	Must be checked against the specific FDA product record
Patent exclusivity	Dependent on Orange Book listings, certifications, litigation, and settlements

Patent expiration dates must be reviewed patent by patent. U.S. Patent No. 8,278,353 has been publicly identified with an expiration date in December 2030, subject to any applicable patent-term adjustment or extension. [2] That patent’s practical impact depends on claim scope, validity, listing status, and whether a generic formulation falls within the asserted claims.

Which companies are challenging VASCEPA?

Hikma Pharmaceuticals was a major U.S. generic challenger. Amarin asserted VASCEPA patents against Hikma, and the Federal Circuit litigation addressed the scope and validity of method-of-use patents. [3]

Other generic manufacturers may enter through:

• Paragraph IV certifications
• Section viii carve-outs
• Paragraph III certifications for later-expiring patents
• Authorized-generic arrangements
• Post-litigation settlement agreements
• ANDA approvals with restricted indications

The competitive threat is strongest for the severe-hypertriglyceridemia indication because a generic can omit the cardiovascular-risk indication if FDA-approved labeling and patent strategy permit the carve-out.

What is the Orange Book status of VASCEPA?

VASCEPA is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The Orange Book identifies approved strengths, dosage forms, therapeutic-equivalence information, and patents or exclusivity data submitted by the NDA holder. [2]

For an excipient-led generic program, the key diligence steps are:

• Confirm all active Orange Book-listed patents for the relevant strength.
• Map each patent claim to the proposed capsule composition.
• Determine whether a section viii statement is available.
• Assess whether the formulation change creates a new patent exposure.
• Review FDA’s therapeutic-equivalence designation after approval.
• Track litigation settlements that limit launch timing or indications.

A shell innovation can improve product differentiation, but it does not replace a complete Orange Book and claim-chart analysis.

What Paragraph IV challenges affect VASCEPA?

Paragraph IV challenges have focused on whether VASCEPA patents are invalid, not infringed, or unenforceable. In the Hikma case, the court found key cardiovascular-risk-reduction claims obvious. [3]

A Paragraph IV strategy for icosapent ethyl typically evaluates:

• Whether the proposed formulation meets the composition claims
• Whether purification limitations are satisfied
• Whether the generic label induces infringement of method claims
• Whether a skinny label removes the patented indication
• Whether manufacturing disclosures create process-patent exposure
• Whether the first-filer position has commercial value

Excipient changes can support a non-infringement argument only when the patent claim requires a specific excipient, shell, ratio, or formulation characteristic. A different plasticizer or antioxidant does not avoid a claim that broadly covers the active pharmaceutical composition.

What formulations are protected by VASCEPA patents?

The principal commercial product is a soft-gel capsule containing icosapent ethyl. The most relevant formulation issues are purity, active concentration, capsule composition, stability, and administration with food.

Potentially protectable formulation improvements include:

• A capsule with lower oxygen permeability
• A defined antioxidant combination
• A low-odor formulation
• A reduced-size high-load capsule
• A composition with improved dissolution under fed and fasted conditions
• A controlled-release or delayed-release presentation
• A stable non-gelatin capsule
• A formulation optimized for patients with swallowing difficulty

A new formulation with a distinct clinical or pharmacokinetic profile may support a 505(b)(2) strategy. A simple excipient substitution generally has stronger commercial value as an ANDA-enabling cost or supply-chain improvement than as a standalone premium product.

How does VASCEPA compare with Lovaza and generic omega-3 products?

VASCEPA competes with omega-3 products but is not interchangeable with fish-oil supplements or all prescription omega-3 products.

Attribute	VASCEPA	Lovaza and generic omega-3 acid ethyl esters	Dietary supplements
Main active	Icosapent ethyl, purified EPA ethyl ester	EPA and DHA ethyl esters	Variable EPA/DHA mixtures
DHA content	No meaningful DHA contribution	Contains DHA	Varies widely
Prescription status	FDA-approved prescription drug	FDA-approved prescription drug	Food product
Cardiovascular indication	Approved for cardiovascular-risk reduction with statin therapy	Not equivalent to VASCEPA’s cardiovascular indication	No equivalent FDA-approved indication
Excipient opportunity	Soft-gel, oxidation control, shell substitution	Similar oil-fill challenges	Broad but less regulated
Generic pathway	ANDA	ANDA	Not applicable
Primary differentiation	EPA-only composition and outcomes data	Mixed EPA/DHA composition	Price, dose, branding, and purity claims

The absence of DHA is commercially relevant because DHA can increase LDL cholesterol in some populations, while VASCEPA is positioned around purified EPA. [1][5]

What manufacturing and IP barriers exist for VASCEPA?

The main barriers are process control and regulatory execution rather than complex excipient intellectual property.

Manufacturing barriers

A commercial manufacturer must control:

• EPA purity and related fatty-acid impurities
• Residual solvents and process contaminants
• Peroxide, anisidine, and total oxidation values
• Fill-weight uniformity
• Capsule seam integrity
• Shell moisture
• Dissolution after accelerated aging
• Light and oxygen exposure
• Packaging oxygen transmission rate

Icosapent ethyl manufacturing also requires a reliable supply of highly purified EPA ethyl ester. Supply agreements, purification know-how, analytical methods, and process patents can create practical barriers even when composition patents are weak.

Excipient supply barriers

Gelatin, glycerin, sorbitol, antioxidants, and capsule-coloring materials are generally available from multiple suppliers. The more important supply risks are:

• Pharmaceutical-grade documentation
• Animal-origin controls for gelatin
• Regional certification requirements
• Batch-to-batch shell performance
• Long-term supply during commodity shortages
• Compatibility with the selected encapsulation line

A vegetarian shell can create a marketing advantage but may introduce greater permeability and process complexity. The decision should be based on stability and cost data rather than label appeal alone.

What licensing deals and regional opportunities exist for VASCEPA?

Amarin has used regional commercialization and licensing arrangements for VASCEPA outside the United States, including arrangements involving Canada and China. [4] Regional partners can create demand for:

• Local soft-gel manufacturing
• Alternate capsule shells
• Region-specific packaging
• Local excipient qualification
• Contract development and manufacturing
• Stability programs for hot and humid climates

Geographic opportunity is strongest where prescription omega-3 products have established reimbursement and where gelatin restrictions or local manufacturing rules favor an alternate capsule platform.

In the United States, generic penetration creates a different opportunity. Suppliers can sell excipient systems, oxygen-control packages, capsule shells, and analytical services to multiple ANDA applicants without competing directly for the finished-dose prescription market.

What generic launch scenarios exist for VASCEPA?

Three scenarios are commercially credible:

Skinny-label launch

A generic launches for severe hypertriglyceridemia while omitting the cardiovascular-risk indication. This approach reduces method-of-use infringement risk and can accelerate entry if remaining composition patents do not block approval or launch.

Full-label launch after patent resolution

A generic launches with both major indications after patent expiration, settlement, or successful litigation. This creates greater substitution potential but carries higher litigation exposure.

Differentiated formulation launch

A developer pursues a 505(b)(2) product with a new capsule shell, improved stability, reduced capsule burden, or modified release. This strategy may support separate patents and pricing, but it requires more evidence than a conventional ANDA.

How strong is the VASCEPA patent estate?

The estate is mixed. Composition and manufacturing claims may provide more durable protection than method-of-use claims, but their strength depends on claim breadth and validity. The Federal Circuit’s decision against key Amarin cardiovascular method claims weakened the enforcement position for that category. [3]

A practical strength assessment is:

Patent category	Relative commercial strength
Broad composition claims	Potentially strong if valid and infringed
Purity and manufacturing claims	Fact-dependent; difficult to assess without process disclosures
Cardiovascular method claims	Weakened by Hikma litigation outcome
Formulation-specific claims	Strong only if narrowly drafted and technically necessary
Pending continuation claims	Requires claim-prosecution and Orange Book review
Non-U.S. patents	Highly jurisdiction-specific

The best defensible formulation patents should link a defined excipient system to measurable advantages such as improved oxidation stability, dissolution, bioavailability, or shelf life.

Key Takeaways

• VASCEPA uses a conventional soft-gel excipient platform centered on gelatin, glycerin, sorbitol, purified water, and oxidation control.
• The main formulation problem is protecting a highly unsaturated lipid from oxidation while maintaining capsule integrity and dissolution.
• The clearest commercial opportunity is a lower-cost, stable, bioequivalent soft-gel generic.
• Vegetarian or vegan capsule shells are potential line extensions but require extensive permeability, stability, and bioequivalence work.
• VASCEPA is a small molecule, so biosimilar risk does not apply. Generic risk under the ANDA pathway does.
• The Hikma litigation weakened key cardiovascular method-of-use patents and supported skinny-label generic entry.
• U.S. development programs must review the current FDA Orange Book listing, patent claims, Paragraph IV exposure, and section viii options.
• Excipient changes can improve manufacturing economics but do not automatically avoid broad composition patents.
• The strongest new IP opportunities involve defined shell, antioxidant, oxygen-control, or release systems tied to measurable product performance.

FAQs About VASCEPA Excipient and Commercial Strategy

Can VASCEPA be reformulated in a vegetarian capsule?

Yes. A vegetarian capsule based on hypromellose, pullulan, or modified starch is technically possible, but the developer must establish equivalent product performance, stability, dissolution, and bioequivalence.

Does VASCEPA contain DHA?

No. VASCEPA contains icosapent ethyl, a purified EPA ethyl ester. It is materially different from mixed EPA/DHA prescription products and fish-oil supplements. [1]

Can a generic use a different antioxidant from VASCEPA?

Potentially. The alternative must be pharmaceutically acceptable, supported by stability data, compatible with the fill and shell, and consistent with ANDA sameness and bioequivalence requirements.

Is VASCEPA eligible for a biosimilar application?

No. VASCEPA is a small-molecule drug. A generic developer would generally use the ANDA pathway, while a materially different formulation or indication may require a 505(b)(2) application.

What is the highest-value excipient patent opportunity for icosapent ethyl?

A patent covering a defined capsule shell or antioxidant system that measurably reduces oxidation, improves shelf life, or preserves dissolution after aging is more commercially defensible than a generic claim to a routine excipient substitution.

References

1. U.S. Food and Drug Administration. (2024). VASCEPA (icosapent ethyl) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Court of Appeals for the Federal Circuit. (2020). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 923 F.3d 1068.
4. Amarin Corporation plc. (2024). Annual report on Form 10-K.
5. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.